

**Feasibility and early outcomes of a tailored quitline protocol for smokers with
mental health conditions.**

Kelly M. Carpenter, PhD¹, Chelsea M. Nash, BA², Robert A. Vargas-Belcher, MPH,
MSW³, Katrina A. Vickerman, PhD¹, Vincent Haufle, DrPH²

¹Optum Center for Wellbeing Research

²Optum Healthcare Analytics

³Optum Prevention and Wellbeing

Corresponding Author:

Kelly Carpenter, PhD

Kelly.Carpenter@Optum.com

Optum Center for Wellbeing Research

11000 Optum Circle

Eden Prairie, MN 55344

206 696-2792

Abstract

Introduction: Adults with mental health conditions (MHCs) smoke at higher rates, are more nicotine dependent, and have more trouble quitting smoking than those without MHCs. About half of smokers who call state-funded quitlines report MHCs, and those with such conditions have cessation rates 8-10% lower than those without MHCs. This paper describes a clinical pilot of a tailored protocol for quitline callers with MHCs. **Methods:** Callers to the Texas Tobacco Quit Line (TXQL) who self-reported MHCs were offered a tailored quitline program, offering up to 12 weeks of combination nicotine replacement (nicotine patch plus gum or lozenge) and seven counseling calls. Characteristics, program engagement, and 7-month outcomes for these pilot participants were compared to callers in the standard TXQL program with and without MHCs not offered the tailored program. **Results:** Eighty-eight percent of eligible quitline callers accepted enrollment in the tailored pilot. Pilot enrollees ($n = 311$) had high rates of co-morbidity and serious mental illness, including bipolar disorder (59%). Those in the pilot sample participated in more coaching calls and used more nicotine replacement versus comparison groups. Early cessation outcomes showed numerically higher quit rates for pilot participants than those with MHCs in the standard program, but small sample size and low response rates prevent definitive statements about efficacy. **Conclusions:** Offering a tailored quitline protocol for callers with MHCs was feasible and acceptable to quitline callers and increased engagement in treatment. A larger study is needed to determine if the protocol increases cessation among this group.

Implications

Nearly half of all quitline callers report a mental health condition. This clinical quality improvement pilot shows that delivering a tailored tobacco cessation program for smokers with mental health conditions is feasible and acceptable to quitline callers. Participants in the pilot group had higher engagement in treatment, doubling the number of coaching calls received and using more nicotine replacement than comparison groups. Further investigation is needed to determine the effect of this program on cessation rates, although preliminary outcomes are promising.

INTRODUCTION

Adults with mental health conditions (MHCs) smoke at higher rates than the general population.¹ Smoking prevalence is particularly high among those with serious mental illness, with recent estimates ranging from 40 to 60% for schizophrenia and bipolar disorder as compared to 17% for those without a MHC.² It is estimated that up to half of those diagnosed with schizophrenia, bipolar disorder, or major depressive disorder will die from tobacco-related illnesses.³ Those with MHCs are not only more likely to smoke, but they are heavier smokers, are more dependent on tobacco, and have more withdrawal symptoms than those without MHCs.^{2,4,5} Barriers to cessation treatment whether financial, systemic (e.g., lack of training for healthcare providers) or cognitive (e.g., beliefs that smoking reduces stress) can be particularly problematic for those with MHC.⁶⁻⁸ However, many smokers with MHCs want to quit smoking and do make cessation attempts.^{9,10} Evidence-based treatments are effective for those with MHC, including serious mental illness and substance use disorders.¹¹ However, even with evidence-based treatment, cessation rates are lower among those with MHCs.^{1,10,12,13} Despite a recent increase in research publications regarding tobacco and MHCs, few studies have evaluated cessation interventions tailored for this disparate population,^{4,14} and many studies exclude those with serious MHCs.¹⁵

Tobacco quitlines provide cessation services to more than 400,000 smokers in the US each year,¹⁶ and about half of callers to state-sponsored quitlines report at least one MHC.^{12,13,17} Recent evidence suggests that state quitline callers with a MHC have less success quitting, with cessation rates 8-10% lower than those without a MHC, despite equivalent engagement in treatment.^{12,13,18,19} Effective interventions to reduce tobacco use and its burden are sorely needed for this disproportionately affected group.⁴

Quitlines are a strongly recommended as treatment strategy by the US Public Health Service (PHS) Guidelines and the National Cancer Institute (NCI) and can reduce barriers to cessation treatment.^{8,20} They are available in all 50 states and two US territories (Washington D.C. and Guam) and provide individual, confidential, free cessation counseling by trained staff in several languages, and most are open seven days a week. Quitlines provide at least a one-call counseling program (when the smoker calls the quitline) and most states provide additional proactive calls (where the quitline calls the smoker to continue treatment, typically for a total of four to five calls).²² Programs providing multiple proactive calls are more efficacious than single-call programs.^{23,24} Quitlines may also offer services via the internet, text messaging, and self-help materials, and some level of nicotine replacement therapy (NRT) is often offered.^{25,26} Quitlines' anonymity, provision of scalable services on a population level, and easy access make them an ideal conduit for specialized tobacco services, but no trials of tailored quitline services for those with MHC have been published.⁴

US PHS Guidelines recommend combining medication and behavioral counseling for the best cessation outcomes.²¹ Questions still remain, however, regarding how to tailor the standard quitline program to best meet the needs of smokers with MHCs. Furthermore, there are also questions about the feasibility of providing services tailored for this population in the context of the quitline where interventions are brief, standardized, and not delivered by mental health counselors.

Given that approximately half of the over 400,000 quitline callers each year report one or more MHC, tailored programs that can be delivered to a large volume of callers through the tobacco quitline model are needed to improve outcomes for callers with MHCs and to continue to decrease overall rates of smoking in the US.^{13,27} Optum, a large service provider of state

quitline services, developed and pilot tested a tailored quitline protocol for those self-reporting one of seven MHCs in partnership with the Texas Tobacco Quit Line (TXQL). This paper reports on the feasibility and preliminary outcomes of this Tobacco Cessation Behavioral Health Program (TCBHP).

METHOD

The pilot study began as a clinical quality improvement project in 2016. Permission to analyze the pilot data and data from comparison groups for research purposes was obtained in July 2017 from the Western Institutional Review Board.

Interventions

Standard Texas Tobacco Quit Line (TXQL) Services (Provided to Comparison Groups)

In the standard TXQL program, participants were offered five coaching calls, and callers who were uninsured, residents of specific counties, or fax-referred were eligible for one 2-week shipment of nicotine patch, gum, or lozenge; Medicaid-insured callers were not eligible for NRT. The PHS Guidelines-based Quit For Life® program is offered by Optum to state quitline participants, and its effectiveness has been well documented.²⁸⁻³² The cessation program emphasizes five keys to quitting tobacco: setting a quit date, using medication, tobacco-proofing the environment, coping with urges and cravings, and garnering social support. The Quit For Life® program typically consists of 4 or 5 calls and is participant-focused with the timing of calls is determined by the participant's quit plan and preferences. Typically quit dates are set 14 to 30 days following the first call (to allow for pre-quit planning and for medication to arrive). All TXQL callers (including pilot participants) could also enroll in an internet intervention (Web Coach®) and/or an automated text messaging program (Text2Quit®). Both Web Coach® and

Text2Quit® are interactive programs. Web Coach® offered an interactive quit plan development module and educational content based on Quit For Life® content in the coaching calls.

Text2Quit® primarily involves being sent text messages tailored around a participant's quit date, but also offers automated interactive texting where a participant can text a keyword to the program (e.g., "crave" when they have a craving) and receive one of several pre-programmed responses (e.g., advice to play a game for distraction).

TCBHP: Tailored Intervention for Smokers with MHC

In general, the TCBHP relied on the same evidence-based treatment model as the standard quitline and utilized strategies aimed at increasing the efficacy of standard quitline protocols (e.g., more interactions with the coach, more and longer duration of NRT). The TCBHP differed from typical quitline services with regard to coaching calls, medication provided, and addition of a letter to medical or mental health providers. The TCBHP was developed by clinicians at Optum with consultation from expert advisers and with reliance on treatment methods prescribed in the PHS Guidelines.²¹

For this pilot, the content of the standard Quit For Life® program was maintained with several changes. First, participants were offered seven calls instead of the standard five calls in order for participants to have more opportunities for tailored support. Number of coaching calls has been found to be related to cessation outcomes in quitline research with more calls leading to better quit rates.²⁹ Standard TXQL and the pilot program participants were attempted three times for each call. Second, stress (a commonly cited reason for relapse) was added as a mandatory assessment question for every call in order to ensure this topic was addressed. Third, coaches were given additional clinical training in working with participants with MHCs that focused on

flexing communication style to match/complement that of the participant. The coaches were also offered additional support and supervision.

NRT has both been shown to be well tolerated and effective for those with MHCs.^{33,34} Combination NRT (using a longer-acting form of NRT such as the patch simultaneously with a shorter-acting form such as the gum or lozenge) has been found to be more effective than monotherapy^{35,36} and was chosen for use in this pilot. Similarly, longer duration of use has been shown to be more effective than shorter duration and 12 weeks of NRT was provided in the pilot.^{36,37} All pilot participants were screened for NRT use exclusions (e.g., recent heart attack, stroke, previous side effects), and those found eligible were offered 12 weeks of combination NRT (i.e., nicotine patch plus choice of gum or lozenge). Standard practice was followed for those participants who reported use exclusions, but wanted to use NRT: they could have a healthcare provider fax a letter to the quitline clearing them for NRT use. Participants were not required to use NRT: if they were unable to or chose not to use NRT, they were still able to participate in the pilot. Further, they could opt for monotherapy (e.g., patch only) rather than combination NRT. NRT was offered in three shipments of four weeks each, and each shipment was triggered by the participant engaging in a coaching call. The first shipment was sent after the first call. The second and third shipments were sent after subsequent calls and timed to prevent the participant running out of medication. Shipment timing was not standardized, however, as participants varied widely in the timing of their calls. NRT use exclusions were re-assessed prior to each shipment being sent.

Finally, the tailored protocol attempted to integrate the callers' mental health provider into treatment: In the first coaching call, participants were asked about a mental health or other provider who could be contacted about the participant's intention to quit tobacco. For

participants who were able to provide contact information (and gave consent), a standardized letter was sent to the provider. The letter contained information about quitting tobacco and tips for how the provider could support the participant in their quit efforts, including advising providers to monitor psychotropic medication dosages in the event changes were needed after cessation.

Participants and Recruitment

TXQL callers who registered during the pilot period (August 8, 2016 through October 13, 2016) were eligible to be screened for the pilot if they were age 18 or older, English speakers, not pregnant, self-referred to the TXQL, enrolled via phone into the call program, and provided a valid phone number. These screening eligibility criteria were also applied to comparison groups. Callers who registered in the standard TXQL five-call program during the pre-pilot period (November 1, 2015 through August 7, 2016) and reported MHCs were included in the standard program with MHCs comparison group (group 1). Callers who registered during the pilot or pre-pilot periods and reported having no MHCs were included in the standard program with no MHCs comparison group (group 2). Callers who enrolled in the pilot were included in group 3. **Figure 1** presents the screening questions and triaged enrollment flow into the three groups.

During the pilot period to ensure that those with the most need of additional services were offered the pilot, a two-step screening process was implemented where all TXQL enrollees with bipolar disorder or schizophrenia were eligible for the pilot, but those reporting other disorders were only eligible if they reported concern that their MHC would interfere with cessation. More specifically, during the pilot period (August 8 through October 13, 2016), callers were asked at enrollment: “Have you ever been diagnosed with any mental health conditions: bipolar disorder, schizophrenia, anxiety disorder, depression, alcohol/drug abuse, or post-

traumatic stress disorder (PTSD)?” Those who said they had been diagnosed with bipolar disorder and/or schizophrenia (population 1) were offered the pilot program. Those who reported that they had not been diagnosed with bipolar disorder or schizophrenia, but had been diagnosed with one of the other disorders (population 2) were asked a second question: “Do you believe that your mental health condition will interfere with your ability to quit and/or stay quit?” If callers answered “yes” or “I don’t know”, they were offered the pilot program. The purpose of this second question was to triage services to those who needed them the most given that state budgets would not allow for all participants with a MHC to participate in the more costly program. Prior to the pilot period the mental health screening question was slightly different: “In the past year, have you ever been diagnosed with or received treatment for any of the following substance abuse, mental health conditions or emotional challenges: depression, anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), drug or alcohol abuse (SUD), schizophrenia?” **Figure 1** illustrates the screening process for the pilot and the comparison groups.

Follow-Up Survey Administration

Follow-up outcome surveys were conducted via email and phone at 7 months post registration. Surveys were attempted on all TCBHP pilot registrants who met sample inclusion criteria. The outcome data for participants in the standard program was collected as part of a previously planned annual evaluation of the TXQL. Approval was obtained to use that already collected data for this analysis. The sample for the program outcome evaluation was selected using random sampling. Additionally, the state of Texas Department of Health requested that all LGBTQ callers be called (census) for outcome evaluation as this is a small priority population. Participants were included in the survey sample if they met the eligibility criteria above,

consented to evaluation follow-up, and completed at least one coaching call. Participants were included in the survey sample only once (regardless of the number of contacts with the TXQL), and only one participant was included per household.

Measures

Demographics and tobacco use data were collected at enrollment. The number of coaching calls, shipments of NRT, Web Coach® login days, and Text2Quit® utilization were recorded and examined as indicators of program engagement. Program satisfaction, last tobacco use, and NRT and prescription cessation medication use were assessed during the 7-month follow-up survey (in that order).

Statistical analysis

Chi-squares and Wilcoxon rank sum tests were conducted in SAS v9.4 (SAS Institute, Inc., Cary, NC, USA) to examine differences in caller characteristics and program engagement. Survey outcomes were weighted to account for differential sampling probabilities among standard program participants; due to the small pilot group size, statistical testing was not conducted on survey outcomes. Multiple imputation was performed using MICE in R v3.4 to impute missing responses to the question assessing MHC interference (which was not asked during the pre-pilot period; see **Figure 1**) and limit to a more appropriate comparison group. Outcomes analyses using multiply imputed data did not differ from analyses of observed data; results present observed (not imputed) data.

RESULTS

Caller characteristics and program engagement analyses include the 11,121 participants who met initial inclusion criteria and enrolled in the pilot (n=311), reported MHCs during the pre-pilot period (n=4933), or reported no MHCs (n=5877) (**Figure 1**). Outcomes analyses focus

on the subset of participants within each group who were included in the final survey sample and responded to the survey: enrolled in the pilot (n=79), reported MHCs during the pre-pilot period (n=223), or reported no MHCs (n=216).

Over half (53.5%) of participants who called the TXQL during the pilot period reported one or more MHCs. As shown in **Figure 1**, the first step of pilot eligibility screening placed 240 participants (45.3%) in population 1 (bipolar and/or schizophrenia; with or without other conditions), and 290 (54.7%) in population 2 (anxiety disorder, depression, alcohol/drug abuse, and/or PTSD; *no* diagnosis of bipolar or schizophrenia). In the second step of eligibility screening (population 2 only), 39% (n=113) of potential population 2 participants answered “yes” or “I don’t know” to the question about their MHC interfering with their ability to quit smoking. After screening, 353 participants were offered the pilot, and 311 (88.1%) accepted enrollment; pilot acceptance rates were similar between populations 1 and 2. Among pilot enrollees, 68% were in population 1 and 32% were in population 2. Co-morbidity was high in the pilot with 86% of population 1 participants also having other disorders such as depression, anxiety, PTSD, or alcohol/drug abuse in addition to bipolar disorder and/or schizophrenia and 61% of population 2 participants reporting two or more conditions. Half (50.5%) of pilot participants provided a mailing address for their healthcare provider (57.4% of population 1; 36.0% of population 2) and letters were sent to those providers.

Characteristics

As shown in Table 1, compared to callers without MHCs, callers with MHCs in the pilot or standard program were more likely to be female, Caucasian, Medicaid- or Medicare-insured (vs. uninsured or commercially insured), divorced or separated (vs. married or in a domestic partnership), smoke within 5 minutes of waking, smoke more cigarettes per day, and use

multiple tobacco types. Callers in both MHC groups were less likely to be heterosexual and have a formal high school degree or greater compared to those without MHC. In addition, pilot participants were less likely to be heterosexual and commercially insured, and more likely to be Caucasian and Medicaid-insured compared to callers with MHC in the standard program. Pilot participants were also far more likely to be diagnosed with bipolar disorder (59.2% vs. 35.5% $p < .0001$) or schizophrenia (21.2% vs. 11.9%, $p < .0001$), and rates of depression, anxiety, and PTSD were slightly higher in the pilot than in the MHC comparison group, likely due to the screening process for the pilot which offered the program to anyone with bipolar or schizophrenia. Pilot participants were also younger, on average, compared to the other two groups.

Engagement

Callers with MHCs in the pilot or standard program were more likely to complete at least one call compared to those without MHCs (85.5% and 84.3% vs. 79.0%, respectively, $p < .0001$). Pilot participants completed nearly twice as many calls (mean = 3.4, $SD = 2.4$) than those in either of the standard program comparison groups (with MHCs mean = 1.7, $SD = 1.3$; without MHCs mean = 1.5, $SD = 1.0$, $p < .0001$). NRT was shipped to more pilot participants (80.1%) as compared to standard program participants with MHC (58.2%, $p < .0001$) and without (38.9%, $p < .0001$); standard program participants with MHC were also more likely to be shipped NRT compared to those without MHC ($p < .0001$). More than one in five (22%) pilot participants received all three NRT shipments (four weeks of NRT in each shipment) offered, and 64% received at least one shipment of combination therapy. With regard to participation in the Text2Quit text messaging program, all groups were equally likely to enroll in the program, but callers with MHC(s) sent more keyword text messages requesting help, on average,

compared to those without MHC(s), and pilot participants sent more keywords compared to standard program participants with MHC(s).

Seven-month outcomes

Due to the small pilot participant group size, statistical testing was not conducted on 7-month survey outcomes; none of the following differences should be interpreted as statistically significant. Survey response rates were higher among participants in the standard program compared to the pilot. As expected, quit rates were highest among callers without MHCs (34.7% respondent 30-day quit rate, 95% CI: 28.7% - 40.7%). Pilot participants had numerically higher quit rates (30.4%, 95% CI: 20.5% - 41.8%) than those with MHC in the standard program (20.8%, 95% CI: 15.2% - 26.4%). Satisfaction and reported NRT use rates also were higher among pilot participants compared to the other two groups. Reported use of prescription cessation medications was similar between groups.

DISCUSSION

This project showed the feasibility of delivering a tailored intervention to quitline callers who report MHCs. The pilot sample had high levels of co-morbidity and serious mental illness, including a high rate of bipolar disorder (nearly 60%). This pilot showed that it is possible to recruit callers into a tailored program, as well as offer and deliver a more robust regimen of NRT and more coaching calls. In fact, those in the pilot of the tailored protocol received twice as many coaching calls as compared to standard program participants. Furthermore, nearly 90% of the pilot sample reported using NRT at follow up (80% were shipped NRT). These factors work synergistically: offering NRT helps initially engage smokers in treatment²⁸ and multiple NRT shipments can increase engagement in follow-up calls, giving callers exposure to the behavioral

components of treatment. Further research is needed to determine if this increased exposure to treatment significantly impacts cessation rates.

Due to the small sample size for the outcome surveys, this project was not adequately powered to examine statistically significant differences in cessation outcomes. However, the pilot exhibited promising preliminary results for individuals with MHC with a 10 percentage point higher quit rate compared to the group of standard program participants with MHCs. The pilot group quit rate was still numerically lower than the quit rate for standard program participants with no MHC. A larger evaluation is needed to determine if the tailored treatment approach improves quit rates and to what degree.

One strength of this pilot is the scalability of the intervention. The Veterans Health Administration (VA) has piloted a specialized telephone treatment protocol for veterans referred by their mental health provider which included up to 10 specialized counseling calls and were supported in their quit attempts by their mental health providers. All patients received medication as prescribed by their VA providers. Participants who received the specialized protocol had better self-reported cessation rates at 6 months (18% vs. 12% intent-to-treat, $p < .01$) as compared to a control condition where participants were told to call their state provided quitline.³⁸ The protocol piloted in this VA study suggests promising outcomes for a well-tailored intervention, but is unlikely to be disseminated in state quitlines as it depends on integration with an in-person mental health clinic and requires medication to be prescribed by a provider. In contrast, the TCBHP protocol is scalable, requiring only bachelor's level cessation specialists and with the ability to ship NRT directly to participants. Further, while integration with a mental health treatment is ideal, many quitline callers do not have such providers and requiring attendance at a clinic is a barrier to treatment for some. In the TCBHP pilot, communication with the mental

health provider was simplified and one-directional (quitline provides information to the provider) and having a mental health provider is not required for participation.

Since this pilot was completed in 2017, several state quitlines have implemented the TCBHP, and several more plan to implement the program in 2019. This dissemination will allow us to evaluate the relative effectiveness of the program on a larger scale.

The primary limitations of this study were the small sample size and low response rate to the 7-month follow-up survey. The low follow-up rates are typical of quitline settings where incentives are rarely offered for survey completion. There were a number of other methodological shortcomings reflecting the real-world nature of the pilot (e.g., differing screening questions, differing methods of calling participants) that would need to be rectified in a more rigorous evaluation of the treatment protocol. A more thorough investigation of the tailored treatment would also include randomization, bioverified quit outcomes, and more detailed information about actual use of quit medications. Contact with providers who received the letter would allow more conclusions to be drawn about the usefulness of that piece of the intervention. Furthermore, additional information about mental health treatment and psychotropic medication use would have allowed us to describe our sample in more detail.

In sum, delivering a tailored quitline protocol for those with behavioral health conditions appears feasible and acceptable to quitline callers and has promising results with regard to engagement and cessation that need to be confirmed in a larger study.

Declaration of Interests

All authors are employees of Optum, the owner of the Quit For Life tobacco cessation program.

Funding

No external funding was provided for this project.

Acknowledgements

We would like to acknowledge the contributions of the Texas Tobacco Quit Line, Ken Wassum clinical director of Quit for Life at the time the intervention was developed, Megan Piper, PhD at the University of Wisconsin Center for Tobacco Research and Intervention who provided consultation, and Etta Short, MS at Optum who assisted with program implementation and coach training.

References

1. Vital signs: current cigarette smoking among adults aged ≥ 18 years with mental illness - United States, 2009-2011. *MMWR*. 2013;62(5):81-87.
2. Dickerson F, Schroeder J, Katsafanas E, et al. Cigarette Smoking by Patients With Serious Mental Illness, 1999-2016: An Increasing Disparity. *Psychiatr Serv. (Washington, DC)*. 2018;69(2):147-153.
3. Callaghan RC, Veldhuizen S, Jeysingh T, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. *J. Psychiatr. Res.* 2014;48(1):102-110.
4. Prochaska JJ, Das S, Young-Wolff KC. Smoking, Mental Illness, and Public Health. *Annu Rev Public Health*. 2017;38:165-185.
5. Sung HY, Prochaska JJ, Ong MK, Shi Y, Max W. Cigarette smoking and serious psychological distress: a population-based study of California adults. *Nicotine Tob Res*. 2011;13(12):1183-1192.
6. McHugh RK, Votaw VR, Fulciniti F, et al. Perceived barriers to smoking cessation among adults with substance use disorders. *J Subst Abuse Treat*. 2017;74:48-53.
7. Rojewski AM, Bailey SR, Bernstein SL, et al. Considering Systemic Barriers to Treating Tobacco Use in Clinical Settings in the United States. *Nicotine Tob Res*. 2018;nty123-nty123.
8. Schoeder S. Making Smoking Cessation Work For People With Mental Illnesses And Other Vulnerable Populations. *Health Affairs Blog*. Vol 2018: Health Affairs; August 23, 2017.
9. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. *Addiction (Abingdon, England)*. 2009;104(5):719-733.
10. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. *Am J Public Health*. 2010;100(12):2464-2472.
11. Das S, Prochaska JJ. Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders. *Expert Rev Respir Med*. 2017;11(10):841-850.
12. Lukowski AV, Morris CD, Young SE, Tinkelman D. Quitline Outcomes for Smokers in 6 States: Rates of Successful Quitting Vary by Mental Health Status. *Nicotine Tob Res*. 2015;17(8):924-930.
13. Vickerman KA, Schauer GL, Malarcher AM, Zhang L, Mowery P, Nash CM. Quitline Use and Outcomes among Callers with and without Mental Health Conditions: A 7-Month Follow-Up Evaluation in Three States. *BioMed res int*. 2015;2015:817298.
14. Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW, Jr. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. *J Gen Intern Med*. 2012;27(3):351-360.
15. Thomson D, Berk M, Dodd S, et al. Tobacco Use in Bipolar Disorder. *Clin Psychopharmacol Neurosci*. 2015;13(1):1-11.
16. NAQC. The use of quitlines among priority populations in the US: Lessons from the scientific evidence. In: Baezconde-Garbanati L, et al., ed. Oakland, CA 2011.
17. Nair US, Bell ML, Yuan NP, Wertheim BC, Thomson CA. Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. *Public health rep. (Washington, DC : 1974)*. 2018;133(2):200-206.
18. Hebert KK, Cummins SE, Hernandez S, Tedeschi GJ, Zhu SH. Current major depression among smokers using a state quitline. *Am. J. Prev. Med*. 2011;40(1):47-53.
19. Tedeschi GJ, Cummins SE, Anderson CM, Anthenelli RM, Zhuang YL, Zhu SH. Smokers with Self-Reported Mental Health Conditions: A Case for Screening in the Context of Tobacco Cessation Services. *PLoS One*. 2016;11(7):e0159127.

20. Fiore M JC, Baker T, Bailey W, Benowitz N, Curry S, Dorfman S, Froelicher E, Goldstein M, Heaton C, et al. Treating Tobacco Use and Dependence:2008 Update. Rockville (MD): US Department of Health and Human Services; 2008.
21. Fiore M JC, Baker T, Bailey W, Benowitz N, Curry S, Dorfman S, Froelicher E, Goldstein M, Heaton C, et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. *Am J Prev Med.* 2008;35(2):158-176.
22. Cummins SE, Bailey L, Campbell S, Koon-Kirby C, Zhu SH. Tobacco cessation quitlines in North America: a descriptive study. *Tob. control.* 2007;16(Suppl 1):i9-i15.
23. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database Sys Rev.* 2013(8):Cd002850.
24. Stead LF, Perera R, Lancaster T. A systematic review of interventions for smokers who contact quitlines. *Tob. Control.* 2007;16 Suppl 1:i3-8.
25. Boal AL, Abrams LC, Simmens S, Graham AL, Carpenter KM. Combined Quitline Counseling and Text Messaging for Smoking Cessation: A Quasi-Experimental Evaluation. *Nicotine Tob Res.* 2016;18(5):1046-1053.
26. Nash CM, Vickerman KA, Kellogg ES, Zbikowski SM. Utilization of a Web-based vs integrated phone/Web cessation program among 140,000 tobacco users: an evaluation across 10 free state quitlines. *J Med Internet Res.* 2015;17(2):e36.
27. Saul J DR, NAQC Annual Survey Workgroup. Results from the 2012 NAQC Annual Survey of Quitlines. *NAQC Annual Survey.* 2013.
28. Bush TM, McAfee T, Deprey M, et al. The impact of a free nicotine patch starter kit on quit rates in a state quit line. *Nicotine Tob Res.* 2008;10(9):1511-1516.
29. Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, Riedlinger K. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. *Tobacco Con.* 2007;16 Suppl 1:i53-59.
30. McAfee TA, Bush T, Deprey TM, et al. Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks. *Am J Prev Med.* 2008;35(2):103-110.
31. Orleans CT, Schoenbach VJ, Wagner EH, et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. *J Consult Clin Psychol.* 1991;59(3):439-448.
32. Zbikowski SM, Jack LM, McClure JB, et al. Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation. *Nicotine Tob Res.* 2011;13(5):319-327.
33. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet.* 2016;387(10037):2507-2520.
34. Roberts E, Eden Evins A, McNeill A, Robson D. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. *Addiction (Abingdon, England).* 2016;111(4):599-612.
35. Smith SS, Keller PA, Kobinsky KH, et al. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. *Nicotine Tob Res.* 2013;15(3):718-728.
36. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Systematic Reviews.* 2013(5):Cd009329.
37. Zhang B, Cohen JE, Bondy SJ, Selby P. Duration of nicotine replacement therapy use and smoking cessation: a population-based longitudinal study. *Am J Epidemiol.* 2015;181(7):513-520.
38. Rogers ES, Smelson DA, Gillespie CC, et al. Telephone Smoking-Cessation Counseling for Smokers in Mental Health Clinics: A Patient-Randomized Controlled Trial. *Am J Prev Med.* 2016;50(4):518-527.

Table 1. Baseline Characteristics of Pilot Participants and Comparison Groups, Collected at Enrollment

Baseline characteristic	Pilot Participants % (n/N)	Standard program participants with MHCs % (n/N)	Standard program participants with no MHCs % (n/N)	p value
Mental health conditions [†]				
Bipolar Disorder	59.2% (184/311)	35.5% (1751/4933)	0.0% (0/5877)	<.0001
Schizophrenia	21.2% (66/311)	11.9% (585/4933)	0.0% (0/5877)	<.0001
Depression	75.6% (235/311)	70.1% (3460/4933)	0.0% (0/5877)	.04
Anxiety Disorder	70.4% (219/311)	60.9% (3003/4933)	0.0% (0/5877)	<.001
Post-Traumatic Stress Disorder	30.9% (96/311)	21.8% (1075/4933)	0.0% (0/5877)	<.001
Substance Abuse Disorder	21.9% (68/311)	19.3% (954/4933)	0.0% (0/5877)	.28
2+ conditions (any)	78.5% (244/311)	62.9% (3104/4933)	0.0% (0/5877)	<.0001
Bipolar and/or Schizophrenia + other condition(s)	58.5% (182/311)	33.1% (1635/4933)	0.0% (0/5877)	<.0001
Gender				
Female	71.4% ^a (222/311)	69.9% ^a (3446/4933)	54.9% ^b (3227/5877)	<.0001
Age				
Mean \pm SD	44.9 ^a \pm 13.3	48.9 ^b \pm 13.1	49.0 ^b \pm 14.4	<.0001
Race				
Caucasian (vs. other races)	73.4% ^a (224/305)	67.2% ^b (3228/4806)	58.9% ^c (3182/5404)	<.0001
Education				
HS degree or greater (vs. GED or < HS)	62.9% ^a (188/299)	66.8% ^a (3184/4765)	72.0% ^b (3868/5370)	<.0001
Health insurance status				
Commercial/private insurance	9.9% ^a (30/303)	16.8% ^b (805/4791)	26.7% ^c (1513/5673)	<.0001
Medicaid	31.7% ^a (96/303)	26.3% ^b (1259/4791)	13.0% ^c (735/5673)	
Medicare	22.4% ^a (68/303)	24.3% ^a (1163/4791)	17.6% ^b (999/5673)	
Uninsured	36.0% ^a (109/303)	32.6% ^a (1564/4791)	42.8% ^b (2426/5673)	
Sexual orientation				
Heterosexual (vs. other orientations)	87.6% ^a (254/290)	92.7% ^b (4325/4668)	95.7% ^c (5005/5228)	<.0001
Marital status				
Single	39.7% (120/302)	37.2% (1770/4755)	37.3% (2006/5376)	<.0001
Divorced or separated	25.5% ^a (77/302)	27.8% ^a (1321/4755)	19.3% ^b (1036/5376)	
Married or in domestic partnership	29.1% ^a (88/302)	26.2% ^a (1244/4755)	34.9% ^b (1878/5376)	
Widowed	5.6% (17/302)	8.8% (420/4755)	8.5% (456/5376)	
Tobacco history at enrollment				
Smoke daily	92.6% (274/296)	94.9% (4467/4708)	95.5% (5096/5339)	.051
Smoke within 5 minutes of waking	58.1% ^a (173/298)	54.8% ^a (2613/4766)	43.2% ^b (2363/5471)	<.0001

Mean cigarettes/day \pm <i>SD</i>	20.6 ^a \pm 12.7	19.3 ^a \pm 11.6	18.1 ^b \pm 10.8	<.0001
Multiple tobacco types	7.4% ^a (23/311)	6.8% ^a (335/4933)	4.3% ^b (255/5877)	<.0001

Note. Responses of “refused”, “don’t know”, and “not collected” are excluded from characteristics analyses. Numbers that share a superscript do *not* significantly differ.

MHC = mental health condition; n = number of respondents; N = group denominator; HS = high school; GED = General Equivalency Diploma.

¹ Multiple conditions reported; results might not add up to 100%.

Accepted Manuscript

Table 2. Program Engagement among Pilot Participants and Comparison Groups

Program engagement metric	Pilot Participants % (n/N)	Standard program participants with MHCs % (n/N)	Standard program participants with no MHCs % (n/N)	<i>p</i> value
Call completion				
Completed at least one coaching call	85.5% ^a (266/311)	84.3% ^a (4159/4933)	79.0% ^b (4642/5877)	<.0001
Mean call completion \pm <i>SD</i> ¹	3.4 ^a \pm 2.4	1.7 ^b \pm 1.3	1.5 ^c \pm 1.0	<.0001
NRT shipments				
Shipped NRT through Quit Line	80.1% ^a (249/311)	58.2% ^b (2871/4933)	38.9% ^c (2287/5877)	<.0001
1 shipment	40.5% (126/311)	58.1% (2867/4933)	38.9% (2283/5877)	--
2 shipments	17.4% (54/311)	0.1% (4/4933)	0.1% (4/5877)	--
3 shipments	22.2% (69/311)	0.0% (0/4933)	0.0% (0/5877)	--
1+ shipments of combination therapy	64.3% (200/311)	0.0% (0/4933)	0.0% (0/5877)	--
Text messaging				
Enrolled in Text2Quit	40.8% (127/311)	38.4% (1894/4933)	36.8% (2161/5877)	.11
Mean Text2Quit key words \pm <i>SD</i> ¹	3.1 ^a \pm 4.3	2.8 ^b \pm 7.6	1.8 ^c \pm 2.8	<.0001
Online engagement				
Enrolled in Web Coach®	52.7% (164/311)	47.9% ^a (2362/4933)	50.8% ^b (2985/5877)	.006
Mean Web Coach® login days \pm <i>SD</i> ¹	4.1 \pm 7.8	3.3 ^a \pm 7.2	2.5 ^b \pm 4.8	<.0001

Note. Numbers that share a superscript do *not* significantly differ.

MHC = mental health condition; n = number of respondents; N = group denominator; NRT = nicotine replacement therapy.

¹ Mean \pm *SD* call completion, Text2Quit key words, and Web Coach® login days reported among those who completed a call, enrolled in Text2Quit, or enrolled in Web Coach.

Table 3. Weighted Survey Outcomes at 7 Months Post Enrollment among Pilot Participants and Comparison Groups

7-month survey outcome (weighted) ^{1,2}	Pilot Participants % (n/N)	Standard program participants with MHCs % (n/N)	Standard program participants with no MHCs % (n/N)	p value
Response rate	35.0% (79/226)	43.1% (206/477)	40.6% (245/603)	--
Satisfaction rate	94.9% (74/78)	88.0% (178/202)	86.3% (203/235)	--
Respondent quit rate				
30-day respondent quit rate	30.4% (24/79)	20.8% (42/200)	34.7% (84/242)	--
Respondent 95% Confidence Interval	20.5% - 41.8%	15.2% - 26.4%	28.7% - 40.7%	--
Intent-to-treat quit rate				
30-day intent-to-treat quit rate	10.6% (24/226)	8.7% (42/477)	13.9% (84/603)	--
Intent-to-treat 95% Confidence Interval	6.9% - 15.4%	6.2% - 11.2%	11.1% - 16.7%	--
Cessation medication use				
Reported NRT use	88.5% (69/78)	62.4% (127/203)	57.5% (140/243)	--
Reported Rx use	10.3% (8/78)	10.8% (22/203)	9.9% (24/243)	--

Note. Responses of “refused”, “don’t know”, and “not collected” are excluded from 7-month survey outcome analyses (with the exception of response rate and intent-to-treat).

MHC = mental health condition; n = number of respondents; N = group denominator; NRT = nicotine replacement therapy; Rx = prescription cessation medication.

¹ Survey outcomes were weighted to account for differential sampling probabilities among standard program participants; ns are approximate and will not match Figure 1.

² Due to the small pilot group size, statistical testing was not conducted on survey outcomes.




Figure 1. Quitline pilot study screening and enrollment flow